Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced financial results for the year ended December 31, 2017.
{iframe}http://investors.rexahn.com/releasedetail.cfm?ReleaseID=1060512{/iframe}